Diabytes
India drugs News
)
Indian government has "privately reassured" industry lobby group US-India Business Council that the country would not invoke 'compulsory licensing' for commercial purposes that could allow local drugmakers to make cheaper products by overriding patents of big global players.
Ranbaxy Laboratories Ltd has sued the U.S. Food and Drug Administration (FDA) for revoking approvals granted to the firm to launch copies of two drugs including AstraZeneca Plc`s heartburn pill Nexium, court documents showed.
The medicines join the 348 drugs deemed essential and that are therefore subject to price caps.
Making more drugs subject to price caps will draw the ire of global drugmakers like Pfizer Inc, GlaxoSmithKline Plc and Abbott Laboratories.
Loading...
 "Will Hindus get justice in Bengal's Murshidabad?")
 "DNA: Uproar over freebies in Delhi!")
 "DNA: AIMIM plans to field 2020 Delhi riots accused Shahrukh Pathan")
 "DNA: A report showing the reality of Bangladesh")
 "DNA: Power Theft Allegations Against SP MP Ziaur Rahman Barq")
 "DNA: Hot Tea Linked to Cancer Risk!")
 "DNA: Why Jordan Fears After Syria’s Coup?")
 "DNA: NSA Ajit Doval’s China Visit - Inside Story")
 "DNA: Gandhi Family Ruined My Career, says Mani Shankar Aiyar")
 "DNA: Ground Report- Tight Security Arrangements for Mahakumbh")
